Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/19/12 | $5,000,000 | Venture Debt |
Silicon Valley Bank | undisclosed |
| 02/12/13 | $10,000,000 |
Aberdare Ventures Merck Global Health Innovation Fund Partners & Partners | undisclosed |
